Format

Send to

Choose Destination
Brain Pathol. 2019 Jul;29(4):469-472. doi: 10.1111/bpa.12732. Epub 2019 May 22.

cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates.

Author information

1
Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
2
Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
3
Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL.
4
Laboratory of Pathology, National Cancer Institute, Bethesda, MD.
5
Department of Neuropathology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
6
Department of Neuropathology, Freie Universität Berlin, Berlin, Germany.
7
Department of Neuropathology, Humboldt-Universität zu Berlin, Berlin, Germany.
8
Department of Neuropathology, Berlin Institute of Health, Berlin, Germany.
9
Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
10
Institute of Neuropathology, University Hospital Munster, Munster, Germany.
11
Department of Pathology, University of California San Francisco, San Francisco, CA.
12
Department of Neuropathology, Heinrich Heine University, Duesseldorf, Germany.
13
German Cancer Consortium (DKTK) partner site Essen/Duesseldorf, Duesseldorf, Germany.
14
Institut de Neurophysiopathology, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Aix-Marseille Univ, APHM, CNRS, Marseille, France.
15
Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University, Heidelberg, Germany.
16
Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
17
German Cancer Consortium (DKTK), Heidelberg, Germany.
18
Department of Pathology, Amsterdam University Medical Centers/VUmc, Amsterdam, The Netherlands.
19
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Abstract

cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established to provide a forum to evaluate and recommend proposed changes to future CNS tumor classifications. From 2016 to 2019 (Round 1), cIMPACT published four updates. Update 1 clarified the use of the term NOS (Not Otherwise Specified) and proposed use of the additional term NEC (Not Elsewhere Classified). Update 2 issued clarifications regarding two diagnoses: Diffuse Midline Glioma, H3 K27M-mutant and Diffuse Astrocytoma/Anaplastic Astrocytoma, IDH-mutant. Update 3 proposed molecular criteria that could be used in the setting of an IDH-wildtype diffuse or anaplastic astrocytic glioma without histological features of glioblastoma to infer that the tumor would behave similarly to a grade IV glioblastoma. Update 4 suggested that, in children and young adults, subtypes of IDH-wildtype/H3-wildtype diffuse gliomas may have distinct clinical features in the setting of a BRAFV600E mutation, FGFR1 alteration, other MAPK pathway alteration, or a MYB or MYBL1 rearrangement. The practical diagnostic relevance of these cIMPACT proposals is highlighted in this summary.

PMID:
31038238
DOI:
10.1111/bpa.12732
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center